Last reviewed · How we verify
Enzira® vaccine
Enzira is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against influenza virus strains.
Enzira is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against influenza virus strains. Used for Seasonal influenza prevention in adults.
At a glance
| Generic name | Enzira® vaccine |
|---|---|
| Also known as | Afluria® vaccine |
| Sponsor | Seqirus |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Enzira contains inactivated (killed) influenza virus antigens that trigger both humoral and cellular immune responses. Upon vaccination, the immune system recognizes these antigens and generates protective antibodies and T-cell responses against circulating influenza strains, reducing the risk of infection and disease severity.
Approved indications
- Seasonal influenza prevention in adults
Common side effects
- Injection site pain or erythema
- Myalgia
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- A Study to Assess the Immunogenicity and Safety of CSL's 2009 / 2010 Formulation of Enzira® Vaccine in Healthy Volunteers (PHASE4)
- A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers (PHASE4)
- A Study to Assess the Immunogenicity and Safety of CSL's 2012/2013 Formulation of Enzira® Vaccine in Healthy Volunteers (PHASE4)
- A Study to Assess the Immunogenicity and Safety of CSL's 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers (PHASE4)
- A Clinical Trial of CSL's 2010/2011 Formulation of Enzira® in a Healthy Adult Population (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enzira® vaccine CI brief — competitive landscape report
- Enzira® vaccine updates RSS · CI watch RSS
- Seqirus portfolio CI